Compare Johnson & Johnson (JNJ) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs NICE Ltd — how do they compare? Johnson & Johnson trades at $248.5 (market cap $598.96B), while NICE Ltd trades at $99.98 (market cap $5.91B). The key difference: Johnson & Johnson is far larger — about 101.3× NICE Ltd's market cap, and Johnson & Johnson pays a 2.15% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| JNJ | NICE | |
|---|---|---|
Market Cap | $598.96B | $5.91B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $170.37 |
52-Week Low | $164.36 | $83.15 |
Enterprise Value | $631.90B | $5.69B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
NICE trades at $101.34, up 1.19% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 17.57% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights AI-driven customer engagement expansions, including a partnership with Banco do Brasil announced on July 14, 2026.
The outlook is positive with a consensus price target of $124.88, implying significant upside. Risks include a projected decline in net income for 2026 and competitive pressures in the technology sector. The absence of sell ratings from analysts underscores underlying strength, but investors should monitor execution against future earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
